20 May 2013
Keywords: solvay, lundbeck, move, bifeprunox, into, ph, iii
Article | 15 September 2003
Belgium-based Solvay Pharmaceuticals and H Lundbeck A/S of Denmark have announced their joint decision to move bifeprunox into Phase ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
15 September 2003
22 September 2003
© 2013 thepharmaletter.com